Use Misoprostol to Optimize Prevention of Cervical Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony typ 3 zmian w szyjce macicy przed losowaniem
- •Wiek 25 lat lub więcej
✗ Disqualifies
- •Typ 1 lub 2 zmian w szyjce macicy
- •Aktualnie w ciąży
- •Usunięta macica
- •Obecne zmiany nowotworowe
- •Aktywne zapalenie szyjki macicy
Simplified criteria — AI translation
Trial details
- Minimum age
- 25 Years
- Last updated (source)
- August 31, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé
Yaoundé, Cameroon
Trial contact
Warner K Huh, MD
Simon M Manga, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.